MBMaaike de Boer

Maaike de Boer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Maaike de Boer has a total of 50 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The gut microbiota during tamoxifen therapy in patients with breast cancer

    by Lars E. Hillege, David J. M. Barnett, Janine Ziemons, Romy Aarnoutse, Judith de Vos-Geelen, Robin van Geel, Maaike de Boer, Yvonne E. A. van Riet, Jeroen Vincent, John Penders, et al.

    Tamoxifen is essential in treating estrogen receptor-positive (ER+) breast cancer, primarily through its active metabolite, endoxifen. Emerging research suggests potential interactions between tamoxifen and gut microbiota. This study investigates the effects of tamoxifen on gut microbiota composition in postmenopausal ER+ and human epidermal growth factor receptor 2 negative (HER2−) breast cancer patients and explores correlations between gut microbiota and endoxifen plasma levels. This prospective observational study included postmenopausal ER+/HER2− breast cancer patients. Fecal and blood samples were collected before and during 6–12 weeks of tamoxifen therapy. Gut microbiota composition was analyzed using 16S rRNA amplicon sequencing of the hypervariable V4 gene region, and plasma endoxifen levels were measured using liquid chromatography-mass spectrometry. Changes in microbial diversity and composition were assessed, with correlations to endoxifen levels. A total of 62 patients were included. Tamoxifen significantly increased microbial richness (p = 0.019), although overall community structure remained consistent between pre- and during-treatment samples. Notable changes were observed in specific microbial taxa, with significant increases in genera such as Blautia (padjusted = 0.003) and Streptococcus (padjusted = 0.010), and decreases in Prevotella_9 (padjusted = 0.006). No significant correlations between gut microbiota and endoxifen levels were identified after multiple comparisons. Tamoxifen therapy increases gut microbial diversity in postmenopausal ER+/HER2− breast cancer patients, though overall microbial community structure remains stable. The absence of significant correlations with endoxifen levels suggests that while tamoxifen affects the gut microbiota, its role in endoxifen metabolism requires further study. More comprehensive research is needed to understand the relationship between tamoxifen, gut microbiota, and therapeutic outcomes.


  • Open Access

    Gene expression profiles in clinically T1-2N0 ER+HER2− breast cancer patients treated with breast-conserving therapy: their added value in case sentinel lymph node biopsy is not performed

    by L. M. van Roozendaal, M. L. G. Vane, E. Colier, L. J. A. Strobbe, M. de Boer, G. Sonke, M. C. Van Maaren, M. L. Smidt

    Purpose: Omitting sentinel lymph node biopsy (SLNB) in breast cancer treatment results in patients with unknown positive nodal status and potential risk for systemic undertreatment. This study aimed to investigate whether gene expression profiles (GEPs) can lower this risk in cT1-2N0 ER+ HER2– breast cancer patients treated with BCT. Methods: Patients were included if diagnosed between 2011 and 2017 with cT1-2N0 ER+ HER2– breast cancer, treated with BCT and SLNB, and in whom GEP was applied. Adjuvant chemotherapy recommendations based on clinical risk status (Dutch breast cancer guideline of 2020 versus PREDICT v2.1) with and without knowledge on SLNB outcome were compared to GEP outcome. We examined missing adjuvant chemotherapy indications, and the number of GEPs needed to identify one patient at risk for systemic undertreatment. Results: Of 3585 patients, 2863 (79.9%) had pN0 and 722 (20.1%) pN + disease. Chemotherapy was recommended in 1354 (37.8% guideline-2020) and 1888 patients (52.7% PREDICT). Eliminating SLNB outcome (n = 722) resulted in omission of chemotherapy recommendation in 475 (35.1% guideline-2020) and 412 patients (21.8% PREDICT). GEP revealed genomic high risk in 126 (26.5% guideline-2020) and 82 patients (19.9% PREDICT) in case of omitted chemotherapy recommendation in the absence of SLNB. Extrapolated to the whole group, this concerns 3.5% and 2.3%, respectively, resulting in the need for 28–44 GEPs to identify one patient at risk for systemic undertreatment. Conclusion: If no SLNB is performed, clinical risk status according to the guideline of 2020 and PREDICT predicts a very low risk for systemic undertreatment. The number of GEPs needed to identify one patient at risk for undertreatment does not justify its standard use.


  • Open Access

    Preserving fertility in young women undergoing chemotherapy for early breast cancer; the Maastricht experience

    by Ingeborg J. H. Vriens, Elena M. ter Welle-Butalid, Maaike de Boer, Christine E. M. de Die-Smulders, Josien G. Derhaag, Sandra M. E. Geurts, Irene E. G. van Hellemond, Ernest J. T. Luiten, M. Wouter Dercksen, Bea M. D. Lemaire, et al.

    Purpose: We assessed the uptake of fertility preservation (FP), recovery of ovarian function (OFR) after chemotherapy, live birth after breast cancer, and breast cancer outcomes in women with early-stage breast cancer. Methods: Women aged below 41 years and referred to our center for FP counseling between 2008 and 2015 were included. Data on patient and tumor characteristics, ovarian function, cryopreservation (embryo/oocyte) and transfer, live birth, and disease-free survival were collected. Kaplan–Meier analyses were performed for time-to-event analyses including competing risk analyses, and patients with versus without FP were compared using the logrank test. Results: Of 118 counseled women with a median age of 31 years (range 19–40), 34 (29%) chose FP. Women who chose FP had less often children, more often a male partner and more often favorable tumor characteristics. The 5-year OFR rate was 92% for the total group of counseled patients. In total, 26 women gave birth. The 5-year live birth rate was 27% for the total group of counseled patients. Only three women applied for transfer of their cryopreserved embryo(s), in two combined with preimplantation genetic diagnosis (PGD) because of BRCA1-mutation carrier ship. The 5-year disease-free survival rate was 91% versus 88%, for patients with versus without FP (P = 0.42). Conclusions: Remarkably, most women achieved OFR, probably related to the young age at diagnosis. Most pregnancies occurred spontaneously, two of three women applied for embryo transfer because of the opportunity to apply for PGD.


  • Open Access

    The correlation of age with chemotherapy-induced ovarian function failure in breast cancer patients

    by Ingeborg J.H. Vriens, Ashley J.R. De Bie, Maureen J.B. Aarts, Maaike de Boer, Irene E.G. van Hellemond, Joyce H.E. Roijen, Ron J.T. van Golde, Adri C. Voogd, Vivianne C.G. Tjan-Heijnen

    The correlation of age with chemotherapy-induced ovarian function failure in breast cancer patients The correlation of age with chemotherapy-induced ovarian function failure in breast cancer patients


  • A real-world study on implementation of bevacizumab in a cohort of HER2-negative metastatic breast cancer patients: A study of the Southeast Netherlands Breast Cancer Consortium

    by R.J.W. van Kampen, D.J.A. Lobbezoo, M. de Boer, M.W. Dercksen, A.C. Voogd, F. van Den Berkmortel, T.J. Smilde, A.J. van de Wouw, F.P.J. Peters, J.M.G. van Riel, et al.